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Abstract
Objective: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia 
(CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and 
mineralocorticoids in CAH.
Design: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-
CAH Registry.
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Methods: Data were collected from 461 patients aged 0–18 years with classic 21-hydroxylase deficiency (54.9% females) 
under follow-up between 1982 and 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement 
were analyzed from 4174 patient visits.
Results: The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences 
between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose 
(median with interquartile range) of 12.0 (10.0–14.5) mg/m2/day at age 1–8 years and the highest dose of 14.0 (11.6–
17.4) mg/m2/day at age 12–18 years. Glucocorticoid doses decreased after 2010 in patients 0–8 years (P < 0.001) and 
remained unchanged in patients aged 8–18 years. Fludrocortisone was used in 92% of patients, with relative doses 
decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone 
replacement.
Conclusions: Data from the I-CAH Registry suggests international variations in hormone replacement therapy, with a 
tendency to treatment with high doses in children.
Introduction
Congenital adrenal hyperplasia (CAH) represents a 
group of autosomal recessive conditions leading to 
glucocorticoid (GC) deficiency. It is caused by defects in the 
steroidogenic enzymes involved in cortisol biosynthesis 
or the electron providing factor P450 oxidoreductase (1, 2, 
3, 4). The most common form, 21-hydroxylase deficiency 
(21OHD), associates significant morbidity and mortality 
(5, 6, 7). Classic CAH due to 21OHD is characterized by 
a complex imbalance of adrenal steroids resulting in 
androgen excess, GC deficiency and, in two-thirds of 
affected individuals, mineralocorticoid deficiency (8). 
Currently, it is almost impossible to mimic the complex 
circadian physiology of adrenal steroid biosynthesis by 
oral glucocorticoid replacement regimes (9). A challenge 
of GC treatment in CAH remains meeting the adequate 
balance between normalization of adrenal androgens, 
often requiring supraphysiological doses, and avoiding 
GC over-exposure, to minimize negative long-term health 
problems (10, 11, 12).
International guidelines aiming to optimize the 
medical management of CAH exist (13, 14, 15). However, 
they remain relatively broad and are likely to result in 
variable clinical practice. Furthermore, given the variability 
in health care provision between different countries, it is 
reasonable to anticipate geographical heterogeneity in 
the medical management of CAH. Thus, it is likely that 
the approach to hormonal replacement therapy in CAH 
is not uniform across the globe, which may represent 
an additional challenge to optimizing management 
and improving health care delivery. In this study, we 
used information available through the International-
CAH Registry (16) and provided evidence for significant 
variation in the current practice of glucocorticoids and 
mineralocorticoid replacement in patients with CAH.
Patients and methods
Study design, setting and participants
We conducted a retrospective international cohort study 
using data recorded in the I-CAH Registry (www.i-cah.
org). The I-CAH Registry is an international database of 
pseudonymized information on patients with CAH and 
is approved by the National Research Ethics Service in the 
United Kingdom as a research database of information 
collected as part of routine clinical care (16). Following 
informed consent from patients or guardians, data are 
deposited within the registry by the endocrinologist 
supervising their management. All patients diagnosed with 
21OHD for whom clinical information was recorded in 
the I-CAH Registry until December 2018 were included in 
the study. Data collection was conducted using the I-DSD/
CAH data fields included in the basic module (register ID, 
center, country, year of birth, age on presentation, disorder 
type, actual diagnosis, sex assigned at birth, current 
gender) and longitudinal module (date of visit, age, weight, 
height, body surface area (BSA), cushingoid features, 
virilization, daily adherence to treatment, glucocorticoid 
type, glucocorticoid dose, timing of glucocorticoid dose, 
fludrocortisone dose, fludrocortisone frequency). For 
children data were collected from each visit for the first 
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2 years of life and then, the first medical visit every year 
until 18 years of age; for adults, data collection included 
the first medical visit in every year over the last 5 years.
Data analysis
Hormone replacement analysis consisted of exploring 
the type of drug used (for glucocorticoids), total daily 
dose and dose for BSA, the timing of administrations 
and distribution of doses throughout the day. BSA 
was calculated using the Mosteller formula (17). We 
established the following age subgroups: less than 1 year, 
1–8 years, 8–12 years, 12–18 years, 18–30 years and more 
than 30-year, corresponding to infancy, early childhood, 
middle childhood, adolescence, young adult stage and 
adulthood respectively. Temporary variations and changes 
in treatment trends were explored by separating data 
before and after 2010, chosen in relation to the guidance 
published by The Endocrine Society (14).
We expressed GC doses for BSA in hydrocortisone 
equivalent, using the conversion rate: 20 mg 
hydrocortisone = 4 mg prednisolone/prednisone = 250 µg 
dexamethasone = 25 mg cortisone acetate, in relation to 
the suppressive effect on the growth of different types 
of synthetic steroids (18, 19). As recommended by The 
Endocrine Society guidelines (15), the target range for 
GC replacement in 21OHD was defined as 10–15 mg 
hydrocortisone/m2/day. Visits reporting intravenous doses 
of GC during acute deteriorations (five patient visits) were 
excluded from the analysis.
Statistical analysis
Data were analyzed using descriptive statistics and ANOVA, 
with appropriate adjustments of statistical tests used in 
accordance to data normality, tested graphically and by 
using the Shapiro–Wilk test. Hormone replacement doses 
between groups were compared by Kruskal–Wallis H, 
Mann–Whitney U and independent T tests. A P value of 
<0.05 was considered statistically significant throughout 
the analysis. Statistical analysis and computation were 
conducted using SPSS Statistics Software version 26 
and GraphPad Prism version 8. In exploring aspects of 
gluco- and mineralocorticoid replacement (daily doses, 
number and timing of doses), we interpreted data from 
every patient visit as an independent variable. For the 
descriptive analysis of different treatment practices in 
different countries, we only included countries that had 
recorded at least 50 patient visits.
Results
The initial dataset included 4732 patient visits that took 
place between 1982 and 2018, of which only 2.6% (6% 
patients) being classified as non-classic CAH (NCCAH). 
Moreover, 89.3% visit related to patients younger than 18 
years, with adult visits only available from three countries 
(seven centers). Consequently, we limited our analysis 
to pediatric visits involving patients with classic 21 
hydroxylase deficiency (Supplementary Fig. 1, see section 
on supplementary materials given at the end of this 
article). We analyzed 4174 visits recording information 
on 461 patients (54.9% females) from 16 countries and 31 
centers (Supplementary Table 1).
Glucocorticoid treatment
Type of glucocorticoids used
Hydrocortisone was used for GC replacement in 90–100% 
visits by all countries with one exception: in Brazil 
cortisone acetate was used in 51.8% visits, hydrocortisone 
in 27.2%, dexamethasone in 13.2% and prednisolone/
prednisone in 6.7%. Prednisone was used in a small 
number of cases: eight visits corresponding to six patients 
from Brazil and the United Kingdom. Dexamethasone 
and prednisolone were used in only 2% of visits in 
children younger than 12 years, and more frequently in 
children aged 12–18 years (dexamethasone 27.6% and 
prednisolone 7.8%). Hydrocortisone was most frequently 
administered following a three daily doses regimen (85%) 
(Fig. 1A). In 8% of patients, different types of GC were 
used over time (Supplementary Table 2).
Glucocorticoid administration regimes
The timing of the GC replacement doses varied widely 
(Fig. 1B and C). The majority of children following a three 
daily GC regime administered the first dose between 6:00 
and 8:00 h, the second dose between 14:00 and 16:00 h 
and the third dose between 22:00 and 23:00 h. For children 
taking four daily doses, the observed trend was for the first 
dose to be given at 4:00 h, the second dose between 11:00 
and 12:00 h, the third dose between 16:00 and 17:00 h 
and last dose at 21:00 h. Of the patient visits reporting 
three and four daily GC administrations, a circadian 
dosing regime was identified in 33.1% and a reverse 
circadian regime in 12.1% of cases, the remaining patients 
receiving at least two equal doses throughout the day. 
There was a significant difference in the administration 
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strategy between age groups (P < 0.001), our results 
showing that a circadian regime was more frequently used 
by children aged 8–12 and 12–18 years (47.4 and 50.5% 
of patient visits, respectively), in comparison to younger 
children. We also found an important increase in the use 
of circadian regimes after 2010 for children older than 1 
year of age (Supplementary Table 3).
Glucocorticoid daily doses for different age groups before 
and after 2010
Daily relative GC doses for BSA (Fig. 2A and Table 1) varied 
significantly among age groups as shown by the Kruskal–
Wallis H test (P < 0.001). Specifically, patients younger 
than 1 year had higher doses than children aged 1–8 years 
(P < 0.001) and 8–12 years (P = 0.030), patients aged 1–8 
years had smaller doses for BSA compared to all other age 
groups (P < 0.001), while patients aged 12–18 years had 
the highest doses among all age groups with significant 
difference compared to the 1–8 years (P < 0.001) and 8–12 
years (P = 0.004) group. Analyzing the clinical practice in 
relation to the international guidelines (14, 15), we found 
that overall the recommended upper limit of 15 mg/m2/
day was exceeded in 37% of patients younger than 1 year 
of age, 21% of 1-8 year olds, 28% within the 8–12 years 
group and 39% of patients in the 12–18 years group. 
No significant difference in relative GC doses between 
genders were found, with the exception of patients aged 
12–18 years, where females received higher doses than 
males (P = 0.002). The fluctuation of GC doses before and 
after 2010 was inconsistent among age and gender groups 
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corresponding to different types of glucocorticoids used in 
children with CAH (A). Timing of glucocorticoid doses for 
children on three daily doses (B) and children on four daily 
doses regimes (C). Each bar represents the number of patient 
visits recording a dose given at that time; the different 
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(A) Glucocorticoid doses expressed as relative hydrocortisone 
equivalent (mg/m2/day) in different age groups. The shaded 
area indicates the recommended dose range of 10–15 mg/m2/
day. The black horizontal lines indicate the median with the 
interquartile range (error bars) for age group. (B) 
Glucocorticoid doses expressed as hydrocortisone equivalent 
(mg/m2/day) in different age groups before (clear circles) and 
after (black squares) 2010. For each subgroup, the circles or 
squares correspond to the median and the error bars to the 
interquartile range. (*Statistical significance in comparing 
doses before and after 2010.) HC, hydrocortisone.
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and subgroups (Fig. 2B, Table 1 and Supplementary Tables 
4, 5).
Taking the variable growth-suppressive effect of 
different artificial GCs into consideration, we explored 
the variations in the HC-equivalent dose for BSA across 
age groups for the different types of drugs used (Table 2). 
Thus, the HC-equivalent doses for BSA were comparable to 
those of hydrocortisone in children treated with cortisone 
acetate for all age groups. The use of dexamethasone and 
prednisolone was limited to a very small number of cases, 
but there was a tendency to exceed the recommended 
dose range.
Glucocorticoid replacement practice in different countries
This analysis only included the 11 countries that recorded 
50 or more patient visits. A comparison of hormone 
replacement between different countries revealed large 
variations in types of medication, doses and regimens 
used. While over 90% of countries/centers used 
hydrocortisone as the preferred GC to treat children, 
in Brazil the use of cortisone acetate was reported in 
51.8% of patient visits, due to limited availability of 
hydrocortisone. Of the 33 patients treated with cortisone 
acetate, four patients received exclusively cortisone 
acetate (during visits recorded before and after 2010), 
12 patients were initially treated with cortisone acetate, 
which was then changed to hydrocortisone at different 
ages between 1 month and 10 years (for all patients 
hydrocortisone was started after 2014), 14 patients were 
treated with cortisone acetate until 12-16 years of age, 
then the treatment was changed to dexamethasone; two 
patients initially received cortisone acetate, followed by 
prednisolone between 4–14 and 10–15 years, respectively, 
then dexamethasone. The use of circadian administration 
regimes varied among countries between 0 and 51.3% 
of patient visits and that of reverse circadian, between 
5.0 and 27.9% (Supplementary Table 6). Exploring 
replacement doses, there were wide variations between 
countries, especially for children younger than 8 years of 
age (Fig. 3, Table 3 and Supplementary Table 7). Observing 
visits recorded in neonates, we noted different strategies 
of initiating GC replacement, with six of ten countries 
using hydrocortisone doses above 7.5 mg/day and some 
having a large variation in doses as wide as 2–15 mg/day 
(corresponding to 6.6–71.8 mg/m2/day HC-equivalent) 
(Supplementary Table 8). While for the majority of 
neonates GC replacement consisted of hydrocortisone, 
six neonates were started on cortisone acetate (dose range 
3–17.5 mg/day, HC-equivalent range 10.5–58.3 mg/m2/
day), five neonates started on prednisolone (dose range 
0.4–1 mg/day, 5–21.1 mg/m2/day HC-equivalent) and one 
Table 1 Glucocorticoid doses for different age groups, 
before and after 2010. The doses are expressed as 












 Overall 1037 375 13.4 (10.3–18.1)
 Before 527 197 14.3 (11.4–20.3)
 After 546 178 12.2 (9.9–16.1)
1–8 years <0.001
 Overall 1893 420 12.0 (10.0–14.5)
 Before 823 187 12.5 (10.3–15.0)
 After 1061 233 11.6 (9.8–13.9)
8–12 years 0.553
 Overall 288 89 13.0 (10.7–15.5)
 Before 104 24 13.0 (7.8–16.5)
 After 184 65 13.0 (11.3–15.1)
12–18 years 0.235
 Overall 259 78 14.0 (11.6–17.4)
 Before 114 22 13.7 (9.6–17.8)
 After 145 56 14.3 (12.1–17.1)
Table 2 Relative doses for different types of glucocorticoids 
used in children. The doses are expressed as HC-equivalent 
(median (interquartile range)).
Patient 
visits, n Patients, n Dose, mg/m2/day
0–1 years
 HC 997 338 13.5 (10.4–18.3)
 CA 55 22 11.4 (9.6–15.4)
 DEX 3 3 17.6–20.5
 PRED 18 4 8.7 (6.4–16.0)
1–8 years
 HC 1740 344 12.0 (10.0–14.4)
 CA 139 23 12.6 (10.1–16.5)
 DEX 1 1 16.7
 PRED 13 5 6.1 (5.4–22.5)
8–12 years
 HC 209 68 12.9 (11.3–15.2)
 CA 73 17 13.0 (7.6–16.0)
 DEX 3 3 20.5–24.2
 PRED 3 2 20.8–19.8
12–18 years
 HC 114 46 13.6 (11.0–15.8)
 CA 44 12 14.0 (8.8–14.8)
 DEX 81 20 13.8 (12.0–20.8)
 PRED 20 11 21.3 (13.9–25.4)
CA, cortisone acetate; DEX, dexamethasone; HC, hydrocortisone; PRED, 
prednisolone.
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started on dexamethasone 0.075 mg/day (17.8 mg/m2/
day HC-equivalent). One center actively reduced the GC 
doses over the first 1–3 months of life, while in the other 
countries initial neonatal doses were maintained, with a 
slowly decreasing relative dose over time.
Fludrocortisone replacement
Ninety-two percent of patients were treated with 
fludrocortisone. The majority of patient visits (60.2%) 
reported a single daily dose of fludrocortisone, 29.8% 
two and 4.7% three daily doses; for the remaining visits, 
fludrocortisone frequency was not specified.
The total daily dose of fludrocortisone ranged between 
50 and 200 µg/day for the vast majority of patients of all 
ages, however, relative fludrocortisone doses varied widely 
across age subgroups (Fig. 4). We identified an increase in 
the dose after 2010 for all ages for both total and relative 
daily doses (Table 4), while no significant differences 
were detected between gender groups (Supplementary 
Table 9). Comparing doses of fludrocortisone between 
countries revealed variations across age groups 
(Supplementary Table 10).





















Glucocorticoid doses used in children from different countries, 
expressed as hydrocortisone equivalent (mg/m2/day). The 
shaded area indicates the recommended dose range of 10–15 
mg/m2/day. The black horizontal lines indicate the median 
with the interquartile range (error bars) for each country. The 
countries included in the analysis were anonymized. We only 
included in the analysis countries that had recorded at least 50 
patient visits. HC, hydrocortisone.
Table 3 Glucocorticoid doses (HC-equivalent) used in 
children from different countries. The results are expressed in 
percentages in relation to a number of patient visits. Only the 











Daily GC doses,  
mg/m2/day
<10 (%) 10–15 (%) > 15 (%)
A 56 13 5.4 35.7 58.9
B 141 24 27.0 56.0 17.0
C 599 57 32.2 41.0 26.7
D 145 17 12.3 28.1 58.9
E 88 22 37.5 38.6 23.9
F 441 57 24.0 50.1 25.9
G 153 27 12.4 41.8 45.8
H 350 56 57.3 32.5 10.0
I 50 9 24.5 75.5
J 760 81 11.3 59.0 29.6
K 693 78 13.5 59.5 25.2
*Country name is anonymized.

























Absolute (A) and relative (B) fludrocortisone (FC) doses for 
different age groups, expressed in µg/day and µg/m2/day, 
respectively. The black horizontal lines indicate the median 
with the interquartile range (error bars) for age group.
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Discussion
Our study explored global trends of hormone replacement 
therapy in children with 21OHD, providing the first 
general overview of the medical management of CAH for 
a wide range of countries across the world. Previous data 
on this topic consisted mainly of literature reviews and 
national cohort studies (20), which made comparisons 
difficult.
Overall, the types of GC used across different 
age groups was in line with the recommendation of 
international guidelines. Hydrocortisone was commonly 
used in children most likely based on its reduced half-
life and risk of adverse effects, especially in relation 
to growth suppression (19, 21, 22). Of note, cortisone 
acetate was used in a relatively high number of children 
and young people in Brazil due to lack of availability of 
oral hydrocortisone preparations. Nevertheless, in over 
90% of patients cortisone acetate was replaced by another 
GC at a later stage. We noted that in some cases this 
was done in younger, prepubertal children after 2014, 
most likely following better access to hydrocortisone 
preparations. In contrast, for patients who were born 
and diagnosed before 2000, dexamethasone replaced 
cortisone acetate after the age of 12 years. While we do 
not have information regarding the clinical reasoning 
that led to these changes, we can speculate that the 
timing is related to the completion of linear growth. 
Using cortisone acetate in children with 21OHD is in line 
with international recommendations; however, previous 
publications described its variable bioactivity in relation 
to the dependency on 11ß-hydroxysteroid dehydrogenase 
type 1, suggesting higher variability of therapeutic 
efficiency (23, 24). We observed a number of children visits 
reporting the use of dexamethasone and prednisolone. 
The published guidelines advise against using long-acting 
GC in children due to the significant growth-suppressive 
effect, especially in the case of dexamethasone (14, 15). 
Since the use of dexamethasone was mainly limited to 
children aged 12–18 years, one might argue that patients 
in this age group may have completed linear growth 
and had more significant problems with complying 
to a three-daily glucocorticoid regime. However, it is 
important to highlight the impact of the type of GC used 
on other health outcomes, as hydrocortisone has been 
also shown to be associated with lower prevalence of 
metabolic comorbidities and better bone health in CAH 
in comparison to dexamethasone (20, 25, 26).
The wide variations in the timing of the GC 
doses may relate to the ongoing debate regarding 
the optimal GC regimen. The majority of children 
received three or four daily doses of short acting GC, 
which resonates with previous research focused on 
optimizing hydrocortisone replacement. Earlier studies 
demonstrated the high bioavailability and fast clearance 
of hydrocortisone, recommending frequent and modest 
daily administrations to better mimic the physiological 
cortisol profiles (27). Furthermore, clinical studies in 
patients with adrenal insufficiency recommended the use 
of three rather than two daily hydrocortisone doses, based 
on improved cortisol profiles (28, 29, 30). We identified a 
rise in the use of circadian administration regimes after 
2010, which is likely related to the increasing focus on 
glucocorticoid regimes following a more physiological 
Table 4 Fludrocortisone doses for different age groups, 









  Overall 1218 379 100 (75–150)
  Before 621 201 100 (62.5–150)
  After 597 178 100 (75–150)
 RD, µg/m2/day <0.001
  Overall 1143 372 312 (209–473)
  Before 567 195 279 (188–416)
  After 576 177 365 (228–536)
1–8 years
 AD, µg/day 0.016
  Overall 2142 417 100 (50–100)
  Before 921 185 94 (50–100)
  After 1221 233 100 (50–100)
 RD, µg/m2/day 0.001
  Overall 2093 414 139 (94–205)
  Before 877 181 149 (99–212)
  After 1216 233 134 (90–195)
8–12 years
 AD, µg/day <0.001
  Overall 278 85 75 (50–125)
  Before 81 21 50 (50–75)
  After 197 64 100 (50–150)
 RD, µg/m2/day <0.001
  Overall 262 82 56 (42–95)
  Before 76 19 45 (38–55)
  After 186 63 74 (44–107)
12–18 years
 AD, µg/day <0.001
  Overall 238 72 100 (50–100)
  Before 75 19 50 (50–50)
  After 163 53 100 (60–150)
 RD, µg/m2/day <0.001
  Overall 221 71 51 (34–77)
  Before 74 18 35 (29–44)
  After 147 53 63 (41–91)
*Presents the statistical difference (Mann-Whitney U) in doses between 
the two time (before and after 2010) intervals.
AD, absolute dose; RD, relative dose.
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circadian pattern (31). Despite limited research evidence 
assessing the benefits of circadian hormone replacement 
in CAH, it represents the most commonly employed 
therapy in clinical practice, based on theoretical and 
practical reasons, aiming to mimic the physiology of 
the hypothalamic–pituitary–adrenal axis (32). Moreover, 
it is well established that evening hydrocortisone doses 
are associated with increased disturbances of glucose 
regulation, including insulin resistance, in comparison to 
morning administrations (33). 
Daily glucocorticoid doses exceeded the 
recommended range of 10–15 mg/m2/day in a third of 
children younger than 1 year and between 12 and 18 
years. However, there was a marked reduction in the 
percentage after 2010 for children younger than 8 years. 
This may relate to the publication of the international 
guidelines in 2002 and 2010 (13, 14). The reason for the 
absence of a similar effect in children aged 8–18 years 
remains unclear. However, adolescents are known to 
have reduced compliance, together with an increasing 
degree of independence and reduced parental 
supervision (34). In addition, cortisol pharmacokinetics 
are altered at puberty in children with CAH by the 
decreased cortisol re-activation, secondary to reduced 
11ß-hydroxysteroid dehydrogenase type 1 activity 
caused by the physiological rise of growth hormone 
and IGF1 (35, 36).
A broad variation between different countries in the 
approach to GC replacement therapy was observed. This 
finding is not entirely unexpected considering previously 
reported variations in GC regimens for different centers 
within the United Kingdom (37). In some countries the 
recommended glucocorticoid dose range for children was 
exceeded in as many as 75% of patient visits, while other 
countries recorded doses below 10 mg/m2 per day in up to 
57% of cases. Overall, infants received very high relative 
doses of GC reaching above 30 mg HC-equivalent/m2 
per day. In neonates there were particularly marked 
differences in clinical practice, with half of the countries 
using hugely variable dose ranges between 4.2–75 mg/
m2 per day HC-equivalent. Only one center actively 
reduced GC doses over the weeks following initiation of 
treatment in a consistent manner. Importantly, studies 
analyzing growth in children with simple virilizing CAH 
and delayed treatment found accelerated growth only 
after the first 12–18 months of life (38, 39), which appears 
to be a consequence of androgen insensitivity in infancy 
(40). In addition, the dose-dependent negative effect of 
GC on linear growth is known and the suppressive action 
is more marked during age intervals of high growth 
velocity, including infancy (41, 42). Moreover, there is 
increased risk of developing metabolic and cardiovascular 
comorbidities in CAH (43), associated with chronic GC 
overexposure (44). Although such comorbidities are only 
becoming fully apparent in adulthood, there is increasing 
evidence of the onset during childhood (45). These points 
emphasize the importance of treatment with the lowest 
possible dose of glucocorticoids by actively reducing 
cumulative GC doses from a young age starting in infants 
and young children.
The large majority of fludrocortisone doses in 
children were within the recommended range of 50–200 
µg/day (15). However, high relative doses were used 
in younger individuals, with doses up to 800 µg/m2 
per day and 600 µg/m2 per day in the under 1 year old 
and 1-8 years old group, respectively. This trend was 
consistent across different countries. We could not assess 
the practice in relation to the dosing strategies used and 
in the absence of information regarding clinical and 
biochemical standards of control it is not possible to 
estimate overtreatment. While there is evidence of renal 
resistance to mineralocorticoids in infants (46, 47), it was 
also shown that fludrocortisone treatment is associated 
with hypertension in children with CAH (48) and there is 
a correlation between blood pressure and fludrocortisone 
dose in infants (49). Thus, our findings indicate that the 
use of absolute doses may lead to overtreatment with 
fludrocortisone, suggesting a potential benefit to using 
relative doses of fludrocortisone at least in young children 
to fine-tune mineralocorticoid replacement.
The aim of this study was to provide an overview on 
the current practice of hormone replacement therapy in 
patients with CAH and we focused mainly on the types of 
medication used, doses and timing of administration. Thus, 
we acknowledge the absence of clinical and biochemical 
data as a weakness of the study and identify the need 
in the future for more in-depth analysis, including such 
information, in order to increase the clinical relevance 
of these findings. Another limitation related to data 
collection, consisting of the overall modest number of 
countries providing information on patients with CAH by 
using the I-CAH Registry, as a limited amount of data was 
available outside of Europe and South America. Moreover, 
the small number of adult patient visits recorded led to 
their exclusion from the analysis. However, the I-CAH 
registry allowed for analysis of a very large dataset in a rare 
condition, highlighting the value of real-world data and 
the benefit of using an international registry as a platform 
for exploring global clinical practice to address questions 
relevant to improving patient management.
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Overall, our results suggest that hormone 
replacement therapy in children and young persons with 
classic 21OHD varies widely across different age groups 
and different countries. It appears that some of these 
discrepancies relate to physicians’ preference rather than 
only to physiological difference between individuals. To 
understand these differences in clinical practice further 
evidence exploring the interdependency of different 
management strategies including CAH monitoring 
methods is urgently warranted. In addition, future 
research should explore if different clinical practices are 
associated with differences in long-term outcome in CAH.
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